Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12526132 | 1.00 | NR1H2 (0.48) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL29126202 | 1.00 | NR1H2 (0.48) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL26923824 | 0.87 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL28484617 | 0.87 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL28476213 | 0.87 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL28704163 | 0.84 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL27268532 | 0.84 | NR1H2 (0.36) | NR1H2RORC | |
| SCHEMBL30613682 | 0.82 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL30613665 | 0.82 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2RECQLRORC | |
| SCHEMBL31235051 | 0.82 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2RECQLRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783199-A | Pyrazolo [1,5-A ] pyrazine derivatives as BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | NR1H2 4351/4885USP2 3640/4885SMN1; SMN2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.